492 Results (Page 17 of 20)
US Markets Research Reports
US X-Linked Myotubular Myopathy (XLMTM) Drugs Market Analysis
US X-Linked Myotubular Myopathy (XLMTM) Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for X-Linked Myotubular Myopathy (XLMTM) Drugs is growing rapidly as a result of unmet medical need for therapies of X-Linked Myotubular Myopathy (XLMTM) disease, advancements in gene therapy, Growing Awareness and Patient Advocacy about the disease, Increased Research and Collaboration between research organizations and pharmaceutical companies, supportive regulatory environments, Technological Advancements in gene sequencing and biomarker identification. Novartis Gene Therapies, Avrobio, Axovant Gene Therapies, Sarepta Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Pfizer, Audentes Therapeutics are the key market players operating in global X-Linked Myotubular Myopathy (XLMTM) Drugs market.
US ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market Analysis
The US ADHD (Attention Deficit Hyperactivity Disorder) Drugs Market is projected to grow from $12.415 Bn in 2022 to $14.776 Bn by 2030, registering a CAGR of 2.20% during the forecast period of 2022-2030. The number of individuals diagnosed with ADHD is on the rise, leading to a higher demand for ADHD medications. Some of the key players in the US ADHD drugs market include Shire (now part of Takeda), Johnson & Johnson, Novartis, Pfizer, Eli Lilly and Company, Concert Pharmaceuticals, Aevi Genomic Medicine, Neos Therapeutics, Vayarin, Supernus Pharmaceuticals.
US Myasthenia Gravis Therapeutics Market Analysis
The US Myasthenia Gravis therapeutics market is projected to grow from $418.4 Mn in 2022 to $724.3 Mn by 2030, registering a CAGR of 7.1% during the forecast period of 2022-30. This market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., and Astellas Pharma, Inc.
US Multiple Sclerosis Therapeutics Market Analysis
The US multiple sclerosis therapeutics market is projected to grow from $18.2 Bn in 2022 to $27.7 Bn by 2030, registering a CAGR of 5.38% during the forecast period of 2022?30. The two reasons propelling market expansion are the prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. Major global players in this market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and Mylan N.V. (U.S.)
US Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
The US Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $7.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $11.4 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of new therapies, a government initiative. The market is segmented by drug class and distribution channel. Some key players in this market are GlaxoSmithKline, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva US Limited, ResMed, Hill-Rom, and others.
US Rheumatology Drugs Market Analysis
The US Rheumatology Drugs Market is projected to grow from $25.641 Bn in 2022 to $27.329 Bn by 2030, registering a CAGR of 0.8% during the forecast period of 2022-2030. The development of new biologic drugs, such as tumour necrosis factor (TNF) inhibitors, interleukin (IL)-6 inhibitors, and Janus kinase (JAK) inhibitors, has expanded the treatment options for rheumatic conditions, driving the market growth. Pfizer is one of the leading pharmaceutical companies in the world and offers a range of rheumatology drugs, including TNF inhibitors and JAK inhibitors.
US ePharmacy Market Analysis
The US ePharmacy Market is projected to grow from $21 Bn in 2022 to $86 Bn by 2030, registering a CAGR of 19.3% during the forecast period of 2022-2030. The US ePharmacy market is driven by a number of factors, including the increasing demand for convenient and cost-effective healthcare solutions, the rise in chronic diseases and the aging population, and the growing adoption of technology in the healthcare industry. CVS Health is one of the largest ePharmacy players in the United States, with a market share of around 25%. The company offers a range of services, including prescription fulfillment, mail-order delivery, and specialty pharmacy services.
US Obesity Drugs Market Analysis
The US obesity drugs market is projected to grow from $1.2 Bn in 2022 to $5.2 Bn by 2030, registering a CAGR of 20.3% during the forecast period of 2022-30. There is increasing awareness of the health risks associated with obesity, including heart disease, diabetes, and high blood pressure. This is driving demand for effective treatments that can help reduce the risk of these conditions. Novo Nordisk, a Danish pharmaceutical company is a major player in the obesity drugs market, with a portfolio of products that includes Saxenda (liraglutide), an injectable drug approved for weight loss in adults with obesity.
US Healthcare Insurance Market Analysis
The US healthcare insurance market is projected to grow from $851 Bn in 2022 to $1316 Bn by 2030, registering a CAGR of 5.6% during the forecast period of 2022-30. The Affordable Care Act (ACA) passed in 2010 significantly impacted the US healthcare insurance market by mandating that individuals carry health insurance coverage and creating insurance marketplaces where consumers can compare and purchase health plans. UnitedHealth Group is the largest healthcare insurance company in the US, with over 50 Mn members across the country.
US 3D Printing Medical Devices Market Analysis
The US 3D printing medical devices market is projected to grow from $1.2 Bn in 2022 to $3.6 Bn by 2030, registering a CAGR of 14.3% during the forecast period of 2022-30. 3D printing enables medical devices to be customized to the individual patient's needs, which can improve patient outcomes and satisfaction. The US 3D printing medical devices market is highly competitive, with several established players and new entrants vying for market share. Some of the major players in the US 3D printing medical devices market include Stratasys, Stryker Corporation, 3D Systems, and Materialise NV
US eHealth Market Analysis
The US eHealth market is projected to grow from $70 Bn in 2022 to $223 Bn by 2030, registering a CAGR of 15.6% during the forecast period of 2022-30. The US eHealth market is driven by factors such as increasing healthcare costs, an aging population, the prevalence of chronic diseases, and the need to improve healthcare outcomes. Digital technologies and services are seen as a way to address these challenges by improving patient engagement, increasing access to care, and reducing healthcare costs. Amazon Pharmacy is a recent entrant to the e-pharmacy market, offering prescription medications and other healthcare products through its online marketplace.
US Depression Therapeutics Market Analysis
The US depression therapeutics market is projected to grow from $4.2 Bn in 2022 to $5.5 Bn by 2030, registering a CAGR of 3.2% during the forecast period of 2022-30. The key players in the market include major pharmaceutical companies such as Pfizer, Inc., Eli Lilly and Company, and Johnson & Johnson, as well as smaller companies, focused on developing innovative new treatments and therapies for depression. Factors driving the growth of the US Depression Therapeutics Market include the increasing prevalence of depression, the growing acceptance of mental health issues, and the development of new and innovative treatments and therapies.
US Cardiovascular Diseases Therapeutics Market Analysis
The US Cardiovascular Disease (CVD) therapeutics market is projected to grow from $68.3 Bn in 2022 to $102.6 Bn by 2030, registering a CAGR of 5.22% during the forecast period of 2022-30. CVD is the leading cause of death in the US and affects a significant portion of the population. This high prevalence of CVD creates a large market for CVD treatments and drives demand for new and innovative therapies. Some of the key players in the US CVD therapeutics market include Pfizer, Novartis, Merck & Co., Sanofi, Bristol-Myers Squibb, and Amgen.
US ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
The US ADHD (Attention Deficit Hyperactivity Disorder) therapeutic market is projected to grow from $12.4 Bn in 2022 to $19.1 Bn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. ADHD is one of the most common neurodevelopmental disorders in children, with an estimated prevalence of 6-9% in the US. The rising prevalence of ADHD is driving the demand for effective treatments and contributing to the growth of the market. Some key players in the US ADHD therapeutic market include Shire (now part of Takeda Pharmaceutical Company), Pfizer Inc., Novartis International AG, Johnson & Johnson, Eli Lilly and Company, and GlaxoSmithKline plc.
US Coronary Stents Market Analysis
The US coronary stents market is projected to grow from $4.7 Bn in 2022 to $5.9 Bn by 2030, registering a CAGR of 2.75% during the forecast period of 2022-30. The US coronary stents market is driven by several factors, including the high prevalence of coronary artery disease (CAD) in the US, advances in stent technology, and increasing demand for minimally invasive procedures. The market is highly competitive, with several major players such as Abbott Laboratories, Boston Scientific Corporation, and Medtronic dominating the market. These companies invest heavily in research and development to develop innovative stent technologies that provide better outcomes for patients.
US Biomaterials in Healthcare Market Analysis
The US biomaterials in the healthcare market are projected to grow from $65.6 Bn in 2022 to $153.4 Bn by 2030, registering a CAGR of 11.2% during the forecast period of 2022-30. Chronic diseases such as cardiovascular disease, cancer, and diabetes are on the rise in the US. The market is highly competitive, with several key players, including BASF SE, DSM NV, Invibio Ltd., Carpenter Technology Corporation, Evonik Industries AG, and Royal DSM. These companies invest heavily in research and development to develop new biomaterials and improve the performance of existing ones.
US Cardiac Monitoring Devices Market Analysis
The US cardiac monitoring device market is projected to grow from $12.1 Bn in 2022 to $15 Bn by 2030, registering a CAGR of 2.7% during the forecast period of 2022-30. The US cardiac monitoring device market is expected to continue growing as the demand for accurate and reliable Cardiac Monitoring devices increases. Medtronic is a leading medical device company that offers a range of cardiac monitoring devices, including implantable cardiac monitors, pacemakers, and defibrillators.
US ENT Devices Market Analysis
The US ENT devices market is projected to grow from $9.7 Bn in 2022 to $13.1 Bn by 2030, registering a CAGR of 3.75% during the forecast period of 2022-30. The rising prevalence of ENT disorders, such as hearing loss, sinusitis, and tonsillitis, is a major driver of the ENT device market. According to the National Institute on Deafness and Other Communication Disorders, approximately 15% of American adults (37.5 million) aged 18 and over report some trouble hearing. The market is highly competitive, with a large number of players operating in the space, ranging from small, specialized companies to large multinational corporations. Some of the key players in the market include Cochlear Limited, William Demant Holding A/S, Medtronic plc, Stryker Corporation, and Olympus Corporation.
US Liver Diseases Therapeutics Market Analysis
The US liver disease therapeutics market is projected to grow from $9.7 Bn in 2022 to $13 Bn by 2030, registering a CAGR of 3.7% during the forecast period of 2022-30. Liver diseases such as hepatitis, liver cancer, and NAFLD are becoming increasingly prevalent in the US population, driving demand for effective treatments. Some of the key players operating in the US liver disease therapeutics market include Gilead Sciences, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb, and Novartis AG. These companies are investing heavily in research and development to develop new and innovative treatments for liver disease and are expected to continue to drive the growth of the market in the coming years.
US Liver Cancer Therapeutics Market Analysis
The US liver cancer therapeutics market is projected to grow from $1.2 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 15.6% during the forecast period of 2022-30. The market for liver cancer therapeutics in the US is driven by factors such as the increasing prevalence of liver cancer, the growing demand for effective treatment options, and advancements in technology and drug development. In addition, the increasing use of combination therapies, the development of targeted therapies, and the focus on personalized medicine are also contributing to the growth of this market. The major players operating in the US liver cancer therapeutics market include pharmaceutical companies such as Bristol-Myers Squibb, Bayer Healthcare, Pfizer Inc., Eisai Co., Ltd., and F. Hoffmann-La Roche AG.
US Infectious Disease Therapeutics Market Analysis
The US infectious disease therapeutics market is projected to grow from $50.3 Bn in 2022 to $60.6 Bn by 2030, registering a CAGR of 2.35% during the forecast period of 2022-30. Antibiotics are one of the most commonly prescribed classes of drugs for infectious diseases, but the rise of antibiotic-resistant bacteria has led to the development of new antibiotics and alternative therapies, such as antivirals and antifungals. Gilead Sciences is a biopharmaceutical company that develops and markets therapeutics for infectious diseases, including HIV/AIDS, hepatitis B and C, and influenza.
US Healthcare Claims Management Market Analysis
The US healthcare claims management market is projected to grow from $11 Bn in 2022 to $53 Bn by 2030, registering a CAGR of 21.4% during the forecast period of 2022-30. Healthcare organizations are increasingly focused on improving patient outcomes and delivering high-quality care. This includes ensuring that claims are processed accurately and quickly so that patients can receive the care they need in a timely manner. There are several key players in the market, including Cerner Corporation, Allscripts Healthcare Solutions, Inc., and McKesson Corporation. These companies offer a range of solutions, including software and services, to help healthcare providers manage their claims and billing processes efficiently.
US Connected Healthcare Market Analysis
The US connected healthcare market is projected to grow from $28 Bn in 2022 to $182 Bn by 2030, registering a CAGR of 26.4% during the forecast period of 2022-30. The US Connected Healthcare market is highly competitive, with a wide range of companies offering products and services in this space. Major players include Apple, Google, Philips, and Samsung, as well as numerous startups and smaller companies. The widespread use of smartphones, tablets, and other mobile devices has led to the growth of mHealth technologies such as mobile health apps, wearables, and telehealth services, which enable patients to receive healthcare services remotely.
US ECG Equipments Market Analysis
The US ECG equipment market is projected to grow from $3.7 Bn in 2022 to $5.7 Bn by 2030, registering a CAGR of 5.3% during the forecast period of 2022-2030. Cardiovascular Diseases (CVDs) are the leading cause of death in the United States, and ECG equipment is an essential tool for diagnosing these conditions. The rising prevalence of CVDs is driving the demand for ECG equipment. Some of the key players in the US ECG equipment market include GE Healthcare, Philips Healthcare, Nihon Kohden Corporation, Hill-Rom Holdings, Inc., and Schiller AG.
US Diabetes Devices Market Analysis
The US diabetes devices market is projected to grow from $4.7 Bn in 2022 to $5.9 Bn by 2030, registering a CAGR of 2.75% during the forecast period of 2022-30. Some of the key trends in the US diabetes devices market include the development of more advanced glucose monitoring and insulin delivery technologies, the use of digital health platforms and apps to help patients manage their diabetes, and the shift towards value-based care models that prioritize patient outcomes and cost-effectiveness. The US diabetes devices market is highly competitive, with several major players dominating the market. Some of the key players in the market include Abbott Laboratories, Medtronic, Dexcom, Roche, and Insulet Corporation.